1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Triptans (Migraine) - Forecast and Market Analysis to 2023

Triptans (Migraine) - Forecast and Market Analysis to 2023

Summary

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Triptans are indicated for the acute treatment of a migraine attack once it has begun, as well as its associated symptoms such as photophobia, phonophobia and nausea. Triptans are selective serotonin (5-HT) receptor agonists that display high affinity for the 5-HT1 class of receptors. Specifically these are the 5-HT1B and 5-HT1D receptor subtypes, as well as some having varying affinity for the 5-HT1F receptor subtype. Each of the individual subtypes has a different mechanism of action. The 5-HT1B subtype causes vasoconstriction in the cranial circulation and in the heart, whereas 5-HT1D subtypes are located on CNS neurons and trigeminal nerve endings.

Scope

- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Triptans including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Beta blockers for the top seven countries from 2012 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Triptans performance
- Obtain sales forecast for Beta blockers from 2012-2023 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Triptans (Migraine) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17
3.2.1 Premonitory Phase 18
3.2.2 Aura Phase 18
3.2.3 Headache Phase 19
3.2.4 Postdrome Phase 19
4 Disease Management 20
4.1 Treatment Overview 20
4.1.1 Acute Migraine Treatment 23
4.1.2 Preventive Migraine Treatment 24
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26
6 Triptans 27
6.1 Overview 27
6.2 SWOT Analysis 29
6.3 Imitrex (sumatriptan) 29
6.3.1 Overview 29
6.3.2 Efficacy 30
6.3.3 Safety 31
6.3.4 Forecast 31
6.4 Zomig (zolmitriptan) 32
6.4.1 Overview 32
6.4.2 Efficacy 33
6.4.3 Safety 34
6.4.4 Forecast 34
6.5 Amerge (naratriptan) 35
6.5.1 Overview 35
6.5.2 Efficacy 35
6.5.3 Safety 36
6.5.4 Forecast 36
6.6 Maxalt (rizatriptan) 37
6.6.1 Overview 37
6.6.2 Efficacy 37
6.6.3 Safety 39
6.6.4 Forecast 39
6.7 Axert (almotriptan) 40
6.7.1 Overview 40
6.7.2 Efficacy 41
6.7.3 Safety 41
6.7.4 Forecast 41
6.8 Frova (frovatriptan) 42
6.8.1 Overview 42
6.8.2 Efficacy 43
6.8.3 Safety 43
6.8.4 Forecast 44
6.9 Relpax (eletriptan) 44
6.9.1 Overview 44
6.9.2 Efficacy 45
6.9.3 Safety 45
6.9.4 Forecast 46
7 Appendix 47
7.1 Bibliography 47
7.2 Abbreviations 51
7.3 Methodology 52
7.4 Forecasting Methodology 52
7.4.1 Diagnosed Migraine Patients 52
7.4.2 Percent Drug-treated Patients 52
7.4.3 General Pricing Assumptions 53
7.4.4 Individual Drug Assumptions 54
7.4.5 Generic Erosion 57
7.5 Physicians and Specialists Included in this Study 58
7.6 Survey of Prescribing Physicians 59
7.7 About the Authors 60
7.7.1 Author 60
7.7.2 Reviewer 60
7.7.3 Global Head of Healthcare 61
7.8 About GlobalData 62
7.9 Disclaimer 62

1.1 List of Tables

Table 1: Classification of Migraine Subtypes 14
Table 2: Diagnostic Criteria for Migraine with Aura 18
Table 3: Diagnostic Criteria for Migraine without Aura 19
Table 4: Treatment Guidelines for Migraine 21
Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013 22
Table 6: Product Profile - Triptans 28
Table 7: Triptans SWOT Analysis, 2013 29
Table 8: Global Sales Forecasts ($m) for Imitrex, 2012-2023 32
Table 9: Global Sales Forecasts ($m) for Zomig, 2012-2023 35
Table 10: Global Sales Forecasts ($m) for Amerge, 2012-2023 37
Table 11: Global Sales Forecasts ($m) for Maxalt, 2012-2023 40
Table 12: Global Sales Forecasts ($m) for Axert, 2012-2023 42
Table 13: Global Sales Forecasts ($m) for Frova, 2012-2023 44
Table 14: Global Sales Forecasts ($m) for Relpax, 2012-2023 46
Table 15: Physicians Surveyed, By Country 59

1.2 List of Figures

Figure 1: Migraine Treatment Algorithm in the 7MM 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Pain Management Drugs and Devices - Global Market Outlook (2016-2022)

Pain Management Drugs and Devices - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Pain Management Drugs and Devices market is expected to grow from $39.48 billion in 2015 to reach $58.2 billion by 2022 with a CAGR of 5.7%. Growing various pain ...

Pain Management Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2023

Pain Management Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2023

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

This report on the pain management therapeutics market studies the current as well as future prospects of the market globally. The pain management therapeutics market report comprises an elaborate executive ...

Global Migraine Drugs Market 2016-2020

Global Migraine Drugs Market 2016-2020

  • $ 2500
  • Industry report
  • May 2016
  • by Infiniti Research Limited

About Migraines A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the US

  • March 2017
    253 pages
  • Therapy  

    Anti-Infective  

    Hormone  

  • United States  

View report >

Therapy Market in the US

  • March 2017
    253 pages
  • Therapy  

    Anti-Infective  

    Hormone  

  • United States  

View report >

Therapy Market in the US

  • March 2017
    253 pages
  • Therapy  

    Anti-Infective  

    Hormone  

  • United States  

View report >

Therapy Market

3 months ago

Related Market Segments :

Antimigraine
Therapy
Pain Relief

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.